ViaCyte
1999
FOUNDED
PRIVATE
STATUS
51-60
EMPLOYEES
Series D
LATEST DEAL TYPE
$80M
LATEST DEAL AMOUNT
29
INVESTORS
Description
Developer of cell and drug therapies intended to treat diabetes and other chronic diseases. The company's therapies are based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device, enabling patients to control type 1 and type 2 blood glucose levels.
Website
Formerly Known As
Novocell
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 3550 General Atomics Court
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore ViaCyte’s full profile, request a free trial.
ViaCyte Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 21. Later Stage VC (Series D) | 29-Nov-2018 | $80M | 00000 | Completed | Generating Revenue | |
| 20. Corporate | 25-Sep-2018 | 0000 | 00000 | Completed | Generating Revenue | |
| 19. Grant | 17-Apr-2018 | 00000 | Completed | Generating Revenue | ||
| 18. Grant | 15-Dec-2017 | 00.00 | 00000 | Completed | Generating Revenue | |
| 17. Later Stage VC | 22-May-2017 | 0000 | 00000 | Completed | Generating Revenue | |
| 16. Grant | 22-May-2017 | 000.00 | 00000 | Completed | Generating Revenue | |
| 15. Grant | 11-Sep-2014 | 000.00 | 00000 | Completed | Generating Revenue | |
| 14. Later Stage VC (Series C1) | 17-Jul-2013 | 000.00 | 00000 | Completed | Generating Revenue | |
| 13. Grant | 26-Oct-2012 | $10.1M | $87.1M | Completed | Generating Revenue | |
| 12. Debt - General | 20-Dec-2011 | $87.1M | Completed | Generating Revenue |
ViaCyte Competitors (27)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Semma Therapeutics | Formerly VC-backed | Cambridge, MA | 00000 | 0&0 | 00000 | |
| 0000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
| 000000000 | Formerly VC-backed | Tucson, AZ | 00 | 000.00 | 000000&0 | 000.00 |
| 0.0. 0000 0000 | Formerly VC-backed | Sunrise, FL | 00 | 000.00 | 000000000 | 000.00 |
| 0000000 | Formerly VC-backed | Leuven, Belgium | 00 | 00000 | 000000&0 | 00000 |
ViaCyte Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 (000000000 | 18-Dec-2015 | 000000000000000000 | Biotechnology | 0000 0000000 00.0 |
ViaCyte Investors (29)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Bain Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| RA Capital Management | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| TPG Biotech | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| CRISPR Therapeutics | Corporation | Minority | 000 0000 | 000000 0 | ||
| The National Institute of Diabetes and Digestive and Kidney Diseases | Government | 000 0000 | 000000 0 |
ViaCyte Executive Team (11)
5 Former Executives
You’re viewing 5 of 11 executives. Get the full list »ViaCyte Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Asish Xavier Ph.D | Self | Board Member | 000 0000 | |
| Donald Elmer | Pacific Horizon Ventures | Board Member | 000 0000 | |
| Franklin Johnson Jr. | Asset Management Ventures | Board Member | 000 0000 | |
| Fred Middleton | Sanderling Ventures | Chairman of the Board | 000 0000 | |
| Mark Foletta | Self | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 9 board members. Get the full list »